Publications

The standard treatment approach for localised Merkel cell carcinoma (MCC) is wide surgical excision followed by adjuvant radiotherapy. However extensive surgery for locally advanced MCC may cause morbidity and disfigurement, compromise function and delay adjuvant...

read more

NCCN Guidelines as published in JNCCN;

NCCN Guidelines as published in JNCCN; Bichakjian, et al The new National Comprehensive Cancer Network (NCCN) guidelines have just been published in the Journal of the National Comprehensive Cancer Network (JNCCN), (Bichakjian, et al). They contain a...

read more

The first-ever

The first-ever phase 3 trial in MCC and is a major academic collaboration across several US cancer centers. - Poster presentation on Mon, Jun 04

read more

ADAM trial:

A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with clinically detected lymph node metastases NCT03271372; Shailender Bhatia et al. A poster...

read more

On Friday 1st June 2018

“On Friday 1st June 2018, Merck/Pfizer announced that the current BAVENCIO (avelumab) metastatic Merkel cell carcinoma access program in Australia will be closed. Any patient request already approved on the access program was grandfathered on Friday, 1st...

read more